WinSanTor’s mission is simple-develop a drug that works. We recognize that there are no treatments for this disease today. Thus, WinSanTor is striving to impact the lives of today’s patients heavily burdened by peripheral neuropathy.

We are impatient. We are exploiting every strategy, mechanism, and regulation to accelerate approval of our drugs, including recycling a previously approved safe drug. We are currently preparing to start our Phase 3 global study for diabetic peripheral neuropathy. Our goal is to get drug approval in the US as soon as possible. By focusing on patient impact rather than the bottom line, we believe we’re creating a new sustainable model for pharma companies based on patient need, not just money.

“We have found what appears to be the first disease-modifying treatment for neuropathy… We [are working to] prevent and reverse the disease.

– Stanley Kim